Xu YW, Tian J, Song Y, Zhang BC, Wang J. Metabolic syndrome’s new therapy: Supplement the gut microbiome. World J Diabetes 2024; 15(4): 793-796 [PMID: 38680700 DOI: 10.4239/wjd.v15.i4.793]
Corresponding Author of This Article
Jing Wang, MD, PhD, Dean, Doctor, Department of Gastroenterology, Songjiang Hospital, School of Medicine, Shanghai Jiaotong University, No. 746 Zhongsanzhong Road, Songjiang District, Shanghai 201600, China. wangj0081@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Apr 15, 2024; 15(4): 793-796 Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.793
Metabolic syndrome’s new therapy: Supplement the gut microbiome
Yong-Wei Xu, Jun Tian, Yan Song, Ba-Cui Zhang, Jing Wang
Yong-Wei Xu, Jun Tian, Yan Song, Ba-Cui Zhang, Jing Wang, Department of Gastroenterology, Songjiang Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 201600, China
Co-first authors: Yong-Wei Xu and Jun Tian.
Author contributions: All authors were involved in the preparation of this work; Xu YW and Tian J designed and reserved the article; Xu YW, Tian J, Song Y, and Zhang BC contributed to the writing of the manuscript; Wang J contributed to the revision of the manuscript.
Supported bythe Songjiang District Tackling Key Science and Technology Research Projects, No. 20sjkjgg32; the Excellent Young Talents Training Program of Songjiang Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, No. QNRC-004; and Science and Technology Project of Songjiang District, No. 22SJKJGG81.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jing Wang, MD, PhD, Dean, Doctor, Department of Gastroenterology, Songjiang Hospital, School of Medicine, Shanghai Jiaotong University, No. 746 Zhongsanzhong Road, Songjiang District, Shanghai 201600, China. wangj0081@126.com
Received: December 20, 2023 Peer-review started: December 20, 2023 First decision: January 17, 2024 Revised: January 18, 2024 Accepted: February 27, 2024 Article in press: February 27, 2024 Published online: April 15, 2024 Processing time: 113 Days and 4.6 Hours
Abstract
This letter to the editor discusses the publication on gut microbiome supplementation as therapy for metabolic syndrome. Gut microbiome dysbiosis disrupts intestinal bacterial homeostasis and is related to chronic inflammation, insulin resistance, cardiovascular diseases, type 2 diabetes mellitus, and obesity. Previous research has found that increasing the abundance of beneficial microbiota in the gut modulates metabolic syndrome by reducing chronic inflammation and insulin resistance. Prebiotics, probiotics, synbiotics, and postbiotics are often used as supplements to increase the number of beneficial microbes and thus the production of short-chain fatty acids, which have positive effects on the gut microbiome and metabolic syndrome. In this review article, the author summarizes the available supplements to increase the abundance of beneficial gut microbiota and reduce the abundance of harmful microbiota in patients with metabolic disorders. Our group is also researching the role of the gut microbiota in chronic liver disease. This article will be of great help to our research. At the end of the letter, the mechanism of the gut microbiota in chronic liver disease is discussed.
Core Tip: I am writing to express my appreciation for the enlightening study titled “Gut microbiome supplementation as therapy for metabolic syndrome” recently published in your esteemed journal. The findings presented in this research shed light on the pivotal role of the gut microbiome in modulating metabolic syndrome, emphasizing the potential therapeutic impact of supplementation. The paper delves into the diverse array of supplements, including probiotics, synbiotics and postbiotics, and their distinct effects on the gut microbiome and its association with metabolic syndrome. I believe that this study will further investigations, inspire clinical trials, and foster the development of targeted interventions to enhance metabolic health through the modulation of the gut microbiome. Our research group is also researching the role of the gut microbiota in chronic liver disease. This article will be of great help to our research.
